SCHEMBL4890645

SCHEMBL4890645

OCc1ccc(-c2ccc3ncnc(Nc4ccc(N5CCOCC5)cc4)c3c2)o1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PI4KB Q9UBF8 1/20 1.00
MAPT P10636 3/20 0.63
HTT P42858 2/20 0.63
MAPK1 P28482 1/20 0.63
AHR P35869 1/20 0.63
EGFR P00533 7/20 0.58
CLK4 Q9HAZ1 2/20 0.53
CLK1 P49759 1/20 0.53
CLK2 P49760 1/20 0.53
DYRK1B Q9Y463 1/20 0.53
DYRK1A Q13627 1/20 0.52
ERBB2 P04626 5/20 0.51
TTBK1 Q5TCY1 1/20 0.49
TTBK2 Q6IQ55 1/20 0.49
NPC1 O15118 1/20 0.48
POLB P06746 1/20 0.48
RAB9A P51151 1/20 0.48
MAPKAPK2 P49137 1/20 0.46
SYK P43405 1/20 0.45
EIF2AK2 P19525 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29360509 1.00 PI4KB (1.00) PI4KBMAPTHTTMAPK1AHR
SCHEMBL4884754 0.90 PI4KB (0.81) PI4KBMAPTHTTMAPK1AHR
SCHEMBL4890468 0.89 PI4KB (0.80) PI4KBMAPTHTTMAPK1AHR
SCHEMBL4882844 0.88 PI4KB (0.78) PI4KBMAPTHTTMAPK1AHR
SCHEMBL4892588 0.86 PI4KB (0.75) PI4KBMAPTHTTMAPK1AHR
SCHEMBL4008515 0.85 MAPT (0.80) PI4KBMAPTHTTMAPK1AHR
SCHEMBL4890642 0.84 PI4KB (0.72) PI4KBMAPTHTTMAPK1AHR
SCHEMBL4892690 0.84 PI4KB (0.72) PI4KBMAPTHTTMAPK1AHR
SCHEMBL4891581 0.82 PI4KB (0.69) PI4KBMAPTHTTMAPK1AHR
SCHEMBL1675015 0.81 PI4KB (0.68) PI4KBMAPK1EGFRCLK4CLK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080311076-A1 Morpholinylanilinoquinazoline Derivatives For Use As Antiviral Agents ARROW THERAPEUTICS LIMITED (GB) 2008-12-18 US disclosed
EP-1748991-A1 MORPHOLINYLANILINOQUINAZO- LINE DERIVATIVES FOR USE AS ANTIVIRAL AGENTS Arrow Therapeutics Limited (GB) 2007-02-07 EP disclosed
WO-2005105761-A1 MORPHOLINYLANILINOQUINAZO- LINE DERIVATIVES FOR USE AS ANTIVIRAL AGENTS ARROW THERAPEUTICS LIMITED (GB) 2005-11-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080311076-A1 Morpholinylanilinoquinazoline Derivatives For Use As Antiviral Agents EIF2AK2, MAVS, IRF3 PI4KB 739/4885MAPT 2064/4885HTT 3581/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.